Premium
LENALIDOMIDE PLUS R‐GDP (R2‐GDP) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA. PRELIMINARY RESULTS OF THE R2‐GDP‐GOTEL TRIAL
Author(s) -
CruzMerino L.,
Martín GarcíaSancho A.,
Nogales Fernández E.,
Carnicero González F.,
Ríos Herranz E.,
Cruz Vicente F.,
Rodríguez García G.,
Nicolás García C.,
Martínez Benaclocha N.,
Gumà Padrò J.,
Gómez Codina J.,
Salar Silvestre A.,
Rodríguez Abreu D.,
Quero Blanco C.,
Labrador Gómez J.,
Guirado Risueño M.,
Provencio Pulla M.,
Rueda Domínguez A.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.67_2630
Subject(s) - lenalidomide , medicine , rituximab , clinical endpoint , diffuse large b cell lymphoma , neutropenia , phases of clinical research , oncology , gastroenterology , multiple myeloma , lymphoma , clinical trial , chemotherapy